title: Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
abstract: Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty-one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension.
authors.affiliation: Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. tsimuni@nmff.org
authors.forename: Tanya
authors.initials: T
authors.lastname: Simuni
authors.forename: Emily
authors.initials: E
authors.lastname: Borushko
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Avram
authors.forename: Scott
authors.initials: S
authors.lastname: Miskevics
authors.forename: Audrey
authors.initials: A
authors.lastname: Martel
authors.forename: C
authors.initials: C
authors.lastname: Zadikoff
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Videnovic
authors.forename: Frances M
authors.initials: FM
authors.lastname: Weaver
authors.forename: Karen
authors.initials: K
authors.lastname: Williams
authors.forename: D James
authors.initials: DJ
authors.lastname: Surmeier
mesh_terms: D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D017275:Isradipine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D002121:Calcium Channel Blockers; D017275:Isradipine